Tetrabenazine improves levodopa-induced peak-dose dyskinesias in patients with Parkinson's disease

Functional Neurology

Volumn 28, Issue 2, 2013, Pages 101-105

  Brusa, Livia ^a   Orlacchio, Antonio ^b,c   Stefani, Alessandro ^b,c   Galati, Salvatore ^d   Pierantozzi, Mariangela ^b,c   Iani, Cesare ^a   Mercuri, Nicola Biagio ^b,c  

^a S EUGENIO HOSPITAL   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^d REGIONAL HOSPITAL OF LUGANO   (Switzerland)

Author keywords

Parkinson's disease; Peak dyskinesia; Quality of life; Vesicular dopamine; Vmat2

Indexed keywords

LEVODOPA; TETRABENAZINE;

ABNORMAL INVOLUNTARY MOVEMENT SCALE; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DYSKINESIA; FEMALE; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; MALE; OPEN STUDY; PARKINSON DISEASE; PILOT STUDY; QUALITY OF LIFE; QUESTIONNAIRE; UNIFIED PARKINSON DISEASE RATING SCALE;

EID: 84885782605     PISSN: 03935264     EISSN: 19713274     Source Type: Journal    
DOI: 10.11138/FNeur/2013.28.1.101     Document Type: Article

References (21)

1. Armstrong MJ, Miyasaki JM, et al (2012) Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology. Neurology 79:597-603
2. Calabresi P, Di Filippo M, Ghiglieri V, et al (2010). Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap. Lancet Neurol 9:1106-1117
3. Giladi N, Melamed E (1999). Levodopa therapy can ameliorate tetrabenazine-induced parkinsonism. Mov Disord; 14:158-159
4. Hayden MR, Leavitt BR, Yasothan U, et al (2009). Tetrabenazine. Nat Rev Drug Discov 8:17-18
5. Horstink M, Tolosa E, Bonuccelli U, et al (2006) Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson's disease. Eur J Neurol 13:1186-1202
6. Jankovic J, Orman J (1988). Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias. Neurology 38:391-394
7. Jenner P (2008). Molecular mechanisms of L-DOPA-induced dyskinesia. Nat Rev Neurosci 9:665-677
8. Lunardi G, Galati S, Tropepi D, et al (2009). Correlation between changes in CSF dopamine turnover and development of dyskinesia in Parkinson's disease. Parkinsonism Relat Disord 15: 383-389
9. Martí-Massó JF, Obeso JA (1985). Coprolalia associated with hemiballismus: response to tetrabenazine. Clin Neuropharmacol 8:189-190
10. Meco G, Stirpe P, Edito F, et al (2009). Aripiprazole in L-dopainduced dyskinesias: a one-year open-label pilot study. J Neural Transm 116: 881-884
11. Mercuri NB, Scarponi M, Federici M, et al (1998). Modification of levodopa responses by deprenyl (selegiline): an electrophysiological and behavioral study in the rat relevant to Parkinson's disease. Ann Neurol 43:613-617
12. Mestre TA, Ferreira JJ (2012). An evidence-based approach in the treatment of Huntington's disease. Parkinsonism Relat Disord 18:316-320
13. Napolitano F, Bonito-Oliva A, Federici M, et al (2010). Role of aberrant striatal dopamine D1 receptor/cAMP/protein kinase A/DARPP32 signaling in the paradoxical calming effect of amphetamine. J Neurosci 30: 11043-11056
14. Olanow CW, Stern MB, Sethi K (2009). The scientific and clinical basis for the treatment of Parkinson disease. Neurology 72:S1-S136
15. Owesson-White CA, Roitman MF, Sombers LA, et al (2012). Sources contributing to the average extracellular concentration of dopamine in the nucleus accumbens. J Neurochem 121:252-262
16. Pahwa R, Factor SA, Lyons KE, et al (2006). Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology; 66:983-995
17. Stefani A, Pierantozzi M, Koch G, et al (2010). Therapy for dyskinesias in Parkinson's disease patients. Future Neurology 5:277-299
18. Stocchi F, Vacca L, Ruggieri S, et al (2005). Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch Neurol 62:905-910
19. Troiano AR, de la Fuente-Fernadez R, Sossi V, et al (2009) PET demonstrates reduced dopamine transporter expression in PD with dyskinesias. Neurology 72: 1211-1216
20. Xu K, Dluzen DE (1998). Alteration in L-DOPA evoked dopamine and DOPAC output under conditions of impaired vesicular dopamine storage. J Neural Transm 105:1091-1101
21. Zheng G, Dwoskin LP, Crooks PA (2006). Vesicular monoamine transporter 2: role as a novel target for drug development. AAPS J 8:E682-E692.